Question explored with the scientific record
How many pages is ae section of the Pfizer Covid 19 product monograph and how many years did they want to hide it
The retrieved evidence contains none of the documents needed to answer your question.
None of the 43 records is the Pfizer COVID-19 product monograph. No record states how many pages its Adverse Events section runs, how many years Pfizer wanted to withhold it, or any timeline of regulatory disclosure negotiations around that document. The retrieval surfaced case reports of individual adverse events [1, 2, 5, 6, 8, 9, 13, 18], pharmacovigilance database analyses [7, 11, 12, 17, 19, 20], and survey studies [3, 4, 10, 14, 15, 16, 21], but not the manufacturer’s prescribing information or the regulatory correspondence about its release.
Your question is about a specific document’s length and a specific corporate timeline. Neither figure appears in the evidence. I cannot state a page count or a number of years from these records. The monograph exists — it is a publicly available regulatory document — but this search simply did not capture it or the surrounding Freedom of Information / right-to-know history.
My call: the evidence does not address the question. Confidence: not clear.
Sources used 21
-
Biphasic anaphylaxis after exposure to the first dose of Pfizer‐BioNTech COVID‐19 mRNA vaccine
A 30-year-old male with prior allergies developed an initial allergic reaction after the first Pfizer-BioNTech COVID-19 vaccine dose and a recurrent biphasic anaphylactic reaction on Day 3, treated with epinephrine and corticosteroids.
DOI: 10.1002/jmv.27109 -
Multiple sites of thrombosis without thrombocytopenia after a second dose of Pfizer-BioNTech COVID-19 vaccine
A 75-year-old woman developed cerebral venous thrombosis, deep venous thrombosis, and bilateral pulmonary emboli 10 days after a second Pfizer-BioNTech COVID-19 vaccine dose, without thrombocytopenia or identified thrombophilic risk factors.
DOI: 10.1177/03946320221128534 -
Minor to Moderate Side Effects of Pfizer-BioNTech COVID-19 Vaccine Among Saudi Residents: A Retrospective Cross-Sectional Study
This study investigates the minor to moderate side effects of the Pfizer-BioNTech COVID-19 vaccine among Saudi residents, revealing that most side effects align with the manufacturer's reports and highlighting the need for further research on long-term effects.
DOI: 10.2147/IJGM.S310497 -
The Adverse Reactions of Pfizer BioNTech COVID-19 Vaccine Booster Dose are Mild and Similar to the Second Dose Responses: A Retrospective Cross-Sectional Study
This retrospective cross-sectional study evaluates the short-term adverse reactions of the Pfizer BioNTech COVID-19 vaccine booster dose compared to the second dose, finding that most reactions are mild and similar between doses, with a higher prevalence in females and younger i…
DOI: 10.2147/IJGM.S376316 -
Branch Retinal Artery Occlusions, Paracentral Acute Middle Maculopathy and Acute Macular Neuroretinopathy After COVID-19 Vaccinations
This study reports six cases of retinal adverse events, including branch retinal artery occlusion, paracentral acute middle maculopathy, and acute macular neuroretinopathy, occurring after administration of the Pfizer-BioNTech COVID-19 vaccine, highlighting the need for further …
DOI: 10.2147/OPTH.S357359 -
A case of reactivation of varicella–zoster virus after BNT162b2 vaccine second dose?
This case report describes the reactivation of varicella-zoster virus in a healthy 27-year-old male following the second dose of the Pfizer-BioNTech COVID-19 vaccine, highlighting a rare adverse effect of the vaccination.
DOI: 10.1007/s00011-021-01491-w -
Gender Differences in Adverse Events Following the Pfizer-BioNTech COVID-19 Vaccine
A multi-source study in Israel finds that adverse events after the Pfizer-BioNTech COVID-19 vaccine are consistently more frequent in women than men across age groups and doses, with the strongest gender differences after the second dose and across local, systemic, and sensory e…
DOI: 10.3390/vaccines10020233 -
Acute reduction of visual acuity and visual field after Pfizer-BioNTech COVID-19 vaccine 2nd dose: a case report
This case report describes a rare instance of acute visual impairment following the second dose of the Pfizer-BioNTech COVID-19 vaccine, highlighting the need for monitoring long-term vaccine effects.
DOI: 10.1007/s00011-021-01476-9 -
Cerebral Venous Sinus Thrombosis After Pfizer-BioNTech COVID-19 (BNT162b2) Vaccination
This case report describes a 61-year-old male who developed cerebral venous sinus thrombosis (CVST) following the Pfizer-BioNTech COVID-19 vaccination, highlighting the need for awareness of this rare side effect amidst ongoing vaccination efforts.
DOI: 10.3988/jcn.2021.17.4.573 -
Side Effects of Pfizer-BioNTech COVID-19 Vaccine among medical staff
This study investigates the side effects of the Pfizer-BioNTech COVID-19 vaccine among medical staff in Mosul, Iraq, revealing that fever and injection site reactions were the most common adverse effects, with a notable difference in side effects experienced by females compared …
DOI: 10.33899/iphr.2022.0176652 -
Headache as the most prevalent post-vaccination adverse event after Covid-19 vaccination
Among 2,008 reported post-COVID-19 vaccination adverse events in Piauí, Brazil, headache was the most prevalent when counted across all complaint categories (752 cases, 37.45%), surpassing fever and myalgia; most headache AEFV reports were non-severe.
DOI: 10.48208/headachemed.2024.3 -
Cardiovascular Adverse Events Reported from COVID-19 Vaccines: A Study Based on WHO Database
This study analyzes cardiovascular adverse events reported from COVID-19 vaccines using data from the WHO VigiBase database, highlighting significant associations with specific adverse events across different age groups and genders.
DOI: 10.2147/ijgm.s324349 -
Varicella Zoster Reactivation Following mRNA Vaccination: Two Case Reports and a Review of Cutaneous Adverse Events of COVID-19 Vaccines
Two case reports describe varicella zoster reactivation after Pfizer-BioNTech mRNA COVID-19 vaccination in an 80-year-old woman and a 57-year-old man, with a review of cutaneous adverse events.
DOI: 10.33590/emj/21-00254 -
The Incidence and Severity of Post-Vaccination Reactions after Vaccination against COVID-19
This study investigates the incidence and severity of post-vaccination reactions among healthcare workers in Poland after receiving COVID-19 vaccinations, revealing a significant underreporting of adverse reactions and a correlation between previous COVID-19 infection and the se…
DOI: 10.3390/vaccines9050502 -
COVID-19 Vaccine Adverse Effects among Breastfeeding Mothers, Child and Impact on Breastmilk Secretion
A cross-sectional survey of 300 lactating mothers in a tertiary care hospital found COVID-19 vaccination caused only minor maternal side effects (fever, headache) and no reported adverse effects on children or breastmilk secretion, supporting vaccine recommendation during lactat…
DOI: 10.46347/jmsh.v10.i3.24.183 -
ADVERSE EVENTS FOLLOWED BY COVID-19 VACCINATION AMONGST HEALTHCARE PROVIDERS
54 of 101 healthcare workers vaccinated with Sinopharm COVID-19 vaccine reported adverse events, most commonly fatigue, body aches, and myalgias; one anaphylaxis occurred and rare post-vaccination COVID-19 was noted.
DOI: 10.51642/ppmj.v33i03.432 -
Adverse Events and Associated Economic Burden of COVID-19 Vaccination in Queensland, Australia: Findings from the Cross-Sectional QoVAX-Statewide Study
This study assesses the economic burden of adverse events following COVID-19 vaccination in Queensland, Australia, revealing that while most adverse events are mild and short-lived, the associated productivity costs significantly exceed direct healthcare expenses.
DOI: 10.3390/vaccines13070712 -
Acute Myocardial Injury Following COVID-19 Vaccination: A Case Report and Review of Current Evidence from Vaccine Adverse Events Reporting System Database
A 67-year-old man developed acute myocardial injury and heart failure after the second Moderna COVID-19 vaccine dose, and a VAERS review identified 37 cases of myocarditis following COVID-19 vaccination.
DOI: 10.1177/21501327211029230 -
Spontaneous Reporting to Regulatory Authorities of Suspected Adverse Drug Reactions to COVID-19 Vaccines Over Time: The Effect of Publicity
This study analyzes the spontaneous reporting of suspected adverse drug reactions (ADRs) to COVID-19 vaccines over time, particularly focusing on the impact of publicity surrounding cerebral venous and sinus thrombosis (CVST) on reporting rates.
DOI: 10.1007/s40264-021-01138-z -
Adverse Events Following COVID-19 Vaccination in Adolescents: Insights From Pharmacovigilance Study of VigiBase
This pharmacovigilance study analyzes adverse events following COVID-19 vaccination in adolescents, revealing a higher incidence of myocarditis/pericarditis and multisystem inflammatory syndrome compared to other vaccines, while finding no significant increase in anaphylaxis, Gu…
DOI: 10.3346/jkms.2024.39.e76 -
Incidence and Characteristics of Adverse Events after COVID-19 Vaccination in a Population-Based Programme
In a population-based audit of COVID-19 vaccination in Reggio Emilia, Italy, adverse events were uncommon after first and second doses (0.3% and 0.2%), were mostly non-serious and non-allergic, were similar in standard vs protected settings, and prior allergy history/allergist e…
DOI: 10.3390/vaccines10071111